Literature DB >> 26423725

Clinical Trials With Mesenchymal Stem Cells: An Update.

Tiziana Squillaro1, Gianfranco Peluso, Umberto Galderisi.   

Abstract

In the last year, the promising features of mesenchymal stem cells (MSCs), including their regenerative properties and ability to differentiate into diverse cell lineages, have generated great interest among researchers whose work has offered intriguing perspectives on cell-based therapies for various diseases. Currently the most commonly used adult stem cells in regenerative medicine, MSCs, can be isolated from several tissues, exhibit a strong capacity for replication in vitro, and can differentiate into osteoblasts, chondrocytes, and adipocytes. However, heterogeneous procedures for isolating and cultivating MSCs among laboratories have prompted the International Society for Cellular Therapy (ISCT) to issue criteria for identifying unique populations of these cells. Consequently, the isolation of MSCs according to ISCT criteria has produced heterogeneous, nonclonal cultures of stromal cells containing stem cells with different multipotent properties, committed progenitors, and differentiated cells. Though the nature and functions of MSCs remain unclear, nonclonal stromal cultures obtained from bone marrow and other tissues currently serve as sources of putative MSCs for therapeutic purposes, and several findings underscore their effectiveness in treating different diseases. To date, 493 MSC-based clinical trials, either complete or ongoing, appear in the database of the US National Institutes of Health. In the present article, we provide a comprehensive review of MSC-based clinical trials conducted worldwide that scrutinizes biological properties of MSCs, elucidates recent clinical findings and clinical trial phases of investigation, highlights therapeutic effects of MSCs, and identifies principal criticisms of the use of these cells. In particular, we analyze clinical trials using MSCs for representative diseases, including hematological disease, graft-versus-host disease, organ transplantation, diabetes, inflammatory diseases, and diseases in the liver, kidney, and lung, as well as cardiovascular, bone and cartilage, neurological, and autoimmune diseases.

Entities:  

Mesh:

Year:  2015        PMID: 26423725     DOI: 10.3727/096368915X689622

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  447 in total

1.  Anti-apoptotic Effects of Human Wharton's Jelly-derived Mesenchymal Stem Cells on Skeletal Muscle Cells Mediated via Secretion of XCL1.

Authors:  SooJin Kwon; Soo Mi Ki; Sang Eon Park; Min-Jeong Kim; Brian Hyung; Na Kyung Lee; Sangmi Shim; Byung-Ok Choi; Duk L Na; Ji Eun Lee; Jong Wook Chang
Journal:  Mol Ther       Date:  2016-06-23       Impact factor: 11.454

2.  Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes.

Authors:  L Zazzeroni; G Lanzoni; G Pasquinelli; C Ricordi
Journal:  CellR4 Repair Replace Regen Reprogram       Date:  2017-09-29

Review 3.  Manufacturing Cell Therapies Using Engineered Biomaterials.

Authors:  Amr A Abdeen; Krishanu Saha
Journal:  Trends Biotechnol       Date:  2017-07-12       Impact factor: 19.536

4.  Survival of aging CD264+ and CD264- populations of human bone marrow mesenchymal stem cells is independent of colony-forming efficiency.

Authors:  Sean D Madsen; Sean H Jones; H Alan Tucker; Margaret K Giler; Dyllan C Muller; Carson T Discher; Katie C Russell; Georgina L Dobek; Mimi C Sammarco; Bruce A Bunnell; Kim C O'Connor
Journal:  Biotechnol Bioeng       Date:  2019-11-12       Impact factor: 4.530

Review 5.  Regenerative medicine in kidney disease: where we stand and where to go.

Authors:  Fernanda T Borges; Nestor Schor
Journal:  Pediatr Nephrol       Date:  2017-07-22       Impact factor: 3.714

6.  Synergistic Effect of Matrix Stiffness and Inflammatory Factors on Osteogenic Differentiation of MSC.

Authors:  Wanting Wan; Bo Cheng; Cheng Zhang; Yufei Ma; Ang Li; Feng Xu; Min Lin
Journal:  Biophys J       Date:  2019-05-25       Impact factor: 4.033

Review 7.  Engineered Mesenchymal Stem Cells for Targeting Solid Tumors: Therapeutic Potential beyond Regenerative Therapy.

Authors:  Shen Cheng; Susheel Kumar Nethi; Sneha Rathi; Buddhadev Layek; Swayam Prabha
Journal:  J Pharmacol Exp Ther       Date:  2019-06-07       Impact factor: 4.030

8.  Poster Viewing Sessions PB01-B01 to PB03-V09.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

9.  IFN-γ-tethered hydrogels enhance mesenchymal stem cell-based immunomodulation and promote tissue repair.

Authors:  José R García; Miguel Quirós; Woojin M Han; Monique N O'Leary; George N Cox; Asma Nusrat; Andrés J García
Journal:  Biomaterials       Date:  2019-08-02       Impact factor: 12.479

10.  Transplanted interleukin-4--secreting mesenchymal stromal cells show extended survival and increased bone mineral density in the murine femur.

Authors:  Tzuhua Lin; Jukka Pajarinen; Yusuke Kohno; Masahiro Maruyama; Monica Romero-Lopez; Jhih-Fong Huang; Karthik Nathan; Tahsin N Khan; Zhenyu Yao; Stuart B Goodman
Journal:  Cytotherapy       Date:  2018-08-02       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.